CONNECT WITH US
HealthTech

HealthTech

Hepatitis B: Controlling the virus does not mean a cure

Medical Xpress logo

Published on

Add as a preferred source on Google
Hepatitis B: Controlling the virus does not mean a cure

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Having a vaccine available is essential for preventing hepatitis B, but it is not enough when part of the population cannot access it.

In Brazil, this challenge is particularly significant in large areas of the Amazon and the North Region of the country, where long distances, limited transportation and low health service availability can hinder vaccination, diagnosis and medical follow-up.

The hepatitis B vaccine is provided free of charge by Brazil's Unified Health System and since 2016 has been available to people of all ages. Even so, people born before the vaccination schedule was expanded or who did not have access to health services may remain at risk. In 2025, approximately 4,600 confirmed cases were recorded in Brazil, according to the Ministry of Health.

These figures represent detected and reported cases, not necessarily all infections acquired in the same year. Since hepatitis B can remain asymptomatic for long periods, many people discover the infection only during routine exams, blood donations, prenatal visits or investigations into other health conditions.

Some patients experience worsening of the infection and develop signs and symptoms similar to acute hepatitis. If patients with chronic hepatitis B progress to cirrhosis, when the liver becomes severely scarred, they will develop signs and symptoms of liver failure, including jaundice , an enlarged spleen , fluid retention in the abdomen , swelling of extremities , especially in the legs and feet, and liver cancer .


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.